Limits...
A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients.

Bachelot T, Gomez F, Biron P, Ray-Coquard I, Soler-Michel P, Philip I, Guastalla JP, Rebattu P, Dumortier A, Droz JP, Blay JY - Br. J. Cancer (2002)

Bottom Line: Haematological toxicity was manageable on an outpatient basis and did not increase significantly with dose escalation.Dose-limiting toxicity was chemotherapy-induced immunosuppression, which resulted in one toxic death and two life-threatening infections.Such therapy allows for high-dose intensity and high cumulative doses on a short period of time with manageable toxicity.

View Article: PubMed Central - PubMed

Affiliation: Département de Cancérologie Médicale Centre Léon Bérard, 28 rue Laënnec, 69373 Lyon Cedex, France. Bachelot@lyon.fnclcc.fr

Show MeSH

Related in: MedlinePlus

Time to treatment failure (dotted line) and overall (solid line) survival of the 28 patients from the first day of chemotherapy.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376188&req=5

fig3: Time to treatment failure (dotted line) and overall (solid line) survival of the 28 patients from the first day of chemotherapy.

Mentions: At the time of analysis, the median follow up was 26 months. The median TTF for the 28 patients was 11 months (95% confidence interval [CI]: 7–15; range 2–61+, Figure 3Figure 3


A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients.

Bachelot T, Gomez F, Biron P, Ray-Coquard I, Soler-Michel P, Philip I, Guastalla JP, Rebattu P, Dumortier A, Droz JP, Blay JY - Br. J. Cancer (2002)

Time to treatment failure (dotted line) and overall (solid line) survival of the 28 patients from the first day of chemotherapy.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376188&req=5

fig3: Time to treatment failure (dotted line) and overall (solid line) survival of the 28 patients from the first day of chemotherapy.
Mentions: At the time of analysis, the median follow up was 26 months. The median TTF for the 28 patients was 11 months (95% confidence interval [CI]: 7–15; range 2–61+, Figure 3Figure 3

Bottom Line: Haematological toxicity was manageable on an outpatient basis and did not increase significantly with dose escalation.Dose-limiting toxicity was chemotherapy-induced immunosuppression, which resulted in one toxic death and two life-threatening infections.Such therapy allows for high-dose intensity and high cumulative doses on a short period of time with manageable toxicity.

View Article: PubMed Central - PubMed

Affiliation: Département de Cancérologie Médicale Centre Léon Bérard, 28 rue Laënnec, 69373 Lyon Cedex, France. Bachelot@lyon.fnclcc.fr

Show MeSH
Related in: MedlinePlus